Surgery for trichiasis, antibiotics to prevent recurrence (STAR) clinical trial methodology

Emily S. West, Wondu Alemayehu, Beatriz Munoz, Muluken Melese, Alemush Imeru, Sheila K. West

Research output: Contribution to journalArticlepeer-review

Abstract

Trachoma is the leading infectious cause of blindness worldwide. Surgery is available to correct trichiasis, which results from repeated episodes of infection with C. trachomatis. However, trichiasis recurrence rates post-surgery are very high. Methods for reducing post-surgical trichiasis recurrence need to be explored. This paper outlines the design of the Surgery for Trichiasis, Antibiotics to prevent Recurrence (STAR) Clinical Trial currently underway in Ethiopia. The STAR trial, funded by The National Eye Institute, is a randomized, controlled clinical trial of antibiotic use at time of trichiasis surgery, comparing topical tetracycline to single-dose azithromycin for the surgical patient and single-dose azithromycin for the surgical patient and all household members. The primary outcome is trichiasis recurrence at one-year. Data from this trial will be critical in helping to determine future policy on antibiotic treatment for C. trachomatis following surgery.

Original languageEnglish (US)
Pages (from-to)279-286
Number of pages8
JournalOphthalmic Epidemiology
Volume12
Issue number4
DOIs
StatePublished - Aug 2005

Keywords

  • Antibiotic therapy
  • Azithromycin
  • Chlamydia trachomatis
  • Ethiopia
  • Star clinical trial
  • Tetracycline
  • Trachoma recurrence
  • Trachoma surgery
  • Trial methodology

ASJC Scopus subject areas

  • Epidemiology
  • Ophthalmology

Fingerprint Dive into the research topics of 'Surgery for trichiasis, antibiotics to prevent recurrence (STAR) clinical trial methodology'. Together they form a unique fingerprint.

Cite this